Tag: BIV201
January 16, 2018
BioVie Reviews Key Accomplishments from 2017 and Updates Phase 2a Clinical Trial
BioVie (OTCQB: BIVI), reviewed key milestones achieved over the past year and provided a general update on the progress of... December 11, 2017
BioVie Obtains FDA Fast Track Designation for BIV201
BioVie announced the FDA granted the company a fast track designation for their orphan drug candidate BIV201. September 28, 2017
BioVie Announces First Patient Dosed in Phase 2a Clinical Trial
BioVie reported the dosing for the first patient in its phase 2a clinical trial of BIV201 for the treatment of... September 14, 2017
BioVie Enrolls First Patient in BIV201 Trial
BioVie confirmed enrollment of the first patient in the Company's mid-stage clinical trial of BIV201. August 29, 2017
BioVie Reports Fiscal Year 2017 Financial Results
BioVie reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress. July 26, 2017
BioVie Files Patent Application in Japan
BioVie filed an application for patent coverage of their new drug candidate BIV201 in Japan. May 24, 2017
